Friday, September 11, 2026

Celltrion’s Three ADC Drug Candidates All Receive FDA Fast Track Designation

Celltrion has secured U.S. FDA Fast Track designation for all three of its antibody-drug conjugate candidates, accelerating development of its emerging oncology drug pipeline.

From Schoolyards to Rainy Drives: ENHYPEN’s Romantic Visuals Stir Hearts

ENHYPEN captivates the hearts of global fans...

Penetrium’s Innovative Cancer Drug Enters Phase 2 Trials in the U.S.: What You Need to Know

Penetrium Bioscience is submitting an IND for Penetrium to start Phase 2 cancer trials in the U.S., leveraging prior safety data.

Tag: CT-P72/ABP-102

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

CT-P72/ABP-102: The Next Big Breakthrough in HER2 Cancer Treatment?

Celltrion's CT-P72/ABP-102 shows strong efficacy against HER2 tumors, promising for treating various cancers with reduced toxicity.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.